NCT05518838 2024-11-08
Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
Oblato, Inc.
No longer available
Oblato, Inc.
Blueprint Medicines Corporation
TVAX Biomedical
Aveta Biomics, Inc.
Kyowa Kirin Co., Ltd.
Istari Oncology, Inc.
Genexine, Inc.
Seagen Inc.
Celldex Therapeutics
Angiochem Inc